All In Biotech

Drug Trial Radar · NCT04534439

Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

A Randomized, Placebo-controlled, Double-blinded, Multi-centre, Phase 2 Study to Assess Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and Nephropathy

Last checked: Nov 20, 2026Latest source record: Aug 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Aug 24, 2020

Primary completion

Jul 26, 2021

Study completion Aug 23, 2021

Sponsor

Lead sponsor
Aptabio Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Sep 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a proof of concept (PoC) trial to evaluate the safety, tolerability and renal effect of APX-115 in subjects with Type 2 diabetes and nephropathy.

Conditions

  • Diabetic Nephropathies
  • Diabetes Mellitus, Type 2
  • Nephropathy, Diabetic

Interventions

  • APX-115Drug

    oral administration of APX-115 400mg capsule once daily for 12 weeks

  • PlaceboDrug

    oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in urine albumin to creatinine ratio (UACR) in APX-115 group compared to placebo groupTime frame: week 12

Locations

16 sites in 4 countries. Site status is shown where the registry gives one.

  • Pleven

    Pleven, Bulgaria

  • Sveta Karidad

    Plovdiv, Bulgaria

  • Diagnostic-consultative centre I

    Sliven, Bulgaria

  • Hadzhi Dimitar

    Sofia, Bulgaria

  • HERA

    Sofia, Bulgaria

  • Medical center - Sveti Dimitar

    Sofia, Bulgaria

  • Sirtuin

    Sofia, Bulgaria

  • Sveta

    Sofia, Bulgaria

  • Hristo Botev

    Vratsa, Bulgaria

  • Sveti Panteleymon Yambol

    Yambol, Bulgaria

  • Nefromed s.r.o

    Prague, Czechia

  • Drug Research Center

    Balatonfüred, Hungary

  • UNO MEDICAL Trials Kft.

    Budapest, Hungary

  • Mint House Private Medical Center

    Székesfehérvár, Hungary

  • Bezanijska Kosa

    Belgrade, Serbia

  • Clinical Centre of Serbia, clinic for endocrinology, diabetes and metabolism diseases, department for obesity, metabolic and reproductive disorders

    Belgrade, Serbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.